Home | Welcome to Contract Pharma   
Last Updated Sunday, November 23 2014
Print

Noven Acquires Minivelle Rights



Published December 3, 2012
Noven Pharmaceuticals has acquired commercial rights to Minivelle (estradiol transdermal system) in the U.S. and Canada from Novogyne Pharmaceuticals, a women’s health joint venture between Noven and Novartis. Financial terms were not disclosed.
 
Noven will market and sell Minivelle through the Women’s Health unit of its subsidiary, Noven Therapeutics, LLC. Noven developed the Minivelle patch using its DOT Matrix transdermal delivery technology, and the product will be manufactured at its Miami, FL facility.
 
Minivelle is approved by the FDA for the treatment of moderate to severe vasomotor symptoms due to menopause. Noven expects that Minivelle will be available in the U.S. in 1Q13.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On